Apricus Biosciences to Present at the 9th Annual LD Micro Main Event
November 29 2016 - 7:00AM
SAN DIEGO, Nov. 29, 2016 (GLOBE
NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a
biopharmaceutical company advancing innovative medicines in urology
and rheumatology, today announced that Richard Pascoe, Chief
Executive Officer, will present at the 9th Annual LD Micro Main
Event on Thursday, December 8, 2016, at 11:30 a.m. Pacific
Time. The conference will be held at the Luxe Sunset Hotel,
in Los Angeles, California. Mr. Pascoe will provide an update
on the Company's strategy and development plans surrounding
Vitaros®.
A live audio webcast of the presentation can be
accessed via the Investor Relations' section of the Company's
website at www.apricusbio.com. Please log in approximately
5-10 minutes before the event to ensure a timely connection. A
replay of the webcast will be available for 30 days following the
presentation.
About Apricus Biosciences,
Inc.
Apricus Biosciences, Inc. (APRI)
is a biopharmaceutical company advancing innovative medicines in
urology and rheumatology. Apricus' commercial product, Vitaros®,
for the treatment of erectile dysfunction, is approved in Canada
and certain countries in Europe, Latin America and the Middle East
and is being commercialized in several countries in Europe. In
September 2015, Apricus in-licensed the U.S. development and
commercialization rights for Vitaros from Allergan. Apricus'
marketing partners for Vitaros include Recordati Ireland Ltd.
(Recordati), Ferring International Center S.A. (Ferring
Pharmaceuticals), Laboratoires Majorelle, Bracco S.p.A., Mylan NV
and Elis Pharmaceuticals Ltd. Apricus currently has one active
product candidate, RayVa(TM), its product candidate for the
treatment of the circulatory disorder Raynaud's phenomenon.
For further information on Apricus,
visit http://www.apricusbio.com.
*Vitaros® is a registered
trademark of NexMed International Limited. Such trademark is
registered in certain countries throughout the world and pending
registration in the United States.
CONTACT:
Institutional / Retail Investors: Matthew Beck
mbeck@troutgroup.com
The Trout Group LLC
(646) 378-2933
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Apricus Biosciences, Inc. via Globenewswire
Apricus Biosciences, Inc. (NASDAQ:APRI)
Historical Stock Chart
From Apr 2024 to May 2024
Apricus Biosciences, Inc. (NASDAQ:APRI)
Historical Stock Chart
From May 2023 to May 2024